Phase I cancer clinical trials.

Area of Science:

• Clinical Pharmacology
• Drug Development
• Biostatistics

Background:

• Phase I trials are essential for assessing new drug safety and determining optimal dosage.
• Identifying the maximum tolerated dose (MTD) is the primary goal for advancing drugs to Phase II.
• Various trial designs exist, each with unique advantages and limitations.

Purpose of the Study:

• To review and compare different Phase I trial designs.
• To highlight the strengths and weaknesses of rule-based and model-based approaches.
• To inform the selection of efficient and safe trial designs.

Main Methods:

• Comparison of rule-based designs (e.g., traditional 3+3, rolling six).
• Evaluation of model-based designs (e.g., continual reassessment method, time-to-event continual reassessment method).
• Review of design characteristics, including ease of implementation and precision in dose estimation.

Main Results:

• Rule-based designs offer simplicity and conservative safety assessment.
• Model-based designs provide enhanced precision in estimating the maximum tolerated dose.
• Each design has specific applications and trade-offs regarding efficiency and safety.

Conclusions:

• The choice of Phase I trial design impacts drug development efficiency and safety.
• Understanding the characteristics of different designs is crucial for optimal trial planning.
• Further research may refine existing designs or introduce novel methodologies.